Publications

Dernière publication 29/10/2021

Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne

Lack of dystrophin causes muscle degeneration, which is exacerbated by chronic inflammation and reduced regenerative capacity of muscle stem cells...

Array
(
    [id_prestablog_news] => 1474
    [id_shop] => 1
    [date] => 2021-10-29 00:00:00
    [date_modification] => 2024-02-09 14:15:13
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [prim_key] => 3184
    [id_lang] => 2
    [title] => Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne 
    [paragraph] => Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy
    [content] => 
Authors
J Dort, Z Orfi, P Fabre et al

 Lab
CHU Sainte-Justine Research Center, Montreal, QC, Canada School of rehabilitation, Faculty of Medicine, Universite de Montreal, Montreal, QC, Canada
Journal
Nature Communications
Abstract
Lack of dystrophin causes muscle degeneration, which is exacerbated by chronic inflammation and reduced regenerative capacity of muscle stem cells in Duchenne Muscular Dystrophy (DMD). To date, glucocorticoids remain the gold standard for the treatment of DMD. These drugs are able to slow down the progression of the disease and increase lifespan by dampening the chronic and excessive inflammatory process; however, they also have numerous harmful side effects that hamper their therapeutic potential. Here, we investigated Resolvin-D2 as a new therapeutic alternative having the potential to target multiple key features contributing to the disease progression. Our in vitro findings showed that Resolvin-D2 promotes the switch of macrophages toward their anti-inflammatory phenotype and increases their secretion of pro-myogenic factors. Moreover, Resolvin-D2 directly targets myogenic cells and promotes their differentiation and the expansion of the pool of myogenic progenitor cells leading to increased myogenesis. These effects are ablated when the receptor Gpr18 is knocked-out, knocked-down, or blocked by the pharmacological antagonist O-1918. Using different mouse models of DMD, we showed that Resolvin-D2 targets both inflammation and myogenesis leading to enhanced muscle function compared to glucocorticoids. Overall, this preclinical study has identified a new therapeutic approach that is more potent than the gold-standard treatment for DMD.
BIOSEB Instruments Used
Grip strength test (BIO-GS3)
    [meta_description] => 
    [meta_keywords] => https://www.nature.com/articles/s41467-021-26516-0
    [meta_title] => 
    [link_rewrite] => resolvin-d2-targets-myogenic-cells-and-improves-muscle-regeneration-in-duchenne-muscular-dystrophy
    [actif_langue] => 1
    [read] => 964
    [count_comments] => 0
    [id] => 1474
    [categories] => Array
        (
            [44] => Array
                (
                    [id_prestablog_categorie] => 44
                    [title] => Myopathie de Duchenne
                    [link_rewrite] => Myopathie-de-Duchenne
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [48] => Array
                (
                    [name] => Test d'agrippement
                    [description_short] => 
Une méthode simple pour quantifier objectivement la force musculaire des rats et souris et l'effet de drogues, toxines, maladies musculaires (ex: myopathie) et neurodégénératives. Cette mesure de force est souvent employée en association avec le test de coordination motrice ROTAROD: un sujet présentant une coordination normale montrera des résultats médiocres en cas de faible force musculaire. Un must pour vos recherches sur l'activité, la coordination et le contrôle musculaire: particulièrement utile pour vos études sur les maladies de Parkinson et Huntington.
Nouveautés GS4 - 2023: Écran couleur rétroéclairé (meilleure lisibilité), pédale de remise à zéro, durée de batterie optimisée, taille de mémoire augmentée à 500 valeurs, compteur d'animaux, port USB (transfert de données/charge)

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/preprod.bioseb.com/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://preprod.bioseb.com/fr/activite-systeme-moteur-coordination/48-grip-strength-test.html
                )

        )

)
1